Key references: Infection with rapidly growing mycobacteria (M. abscessus, M. chelonae and M. fortuitum)

  • Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017;72(Suppl 2):ii1–ii64. https://www.ncbi.nlm.nih.gov/pubmed/29054853
  • Mukherjee V, Bender WS, Egan JP 3rd. Inhaled antibiotics for refractory nontuberculous mycobacteria and non-cystic fibrosis bronchiectasis and the significance of Mycobacterium abscessus subsp. abscessus isolation during M. avium complex lung disease therapy. Am J Respir Crit Care Med 2015;192(1):106–8. https://www.ncbi.nlm.nih.gov/pubmed/26131990
  • Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis 2017;64(3):301–308. https://www.ncbi.nlm.nih.gov/pubmed/28011609
  • Zhang Z, Lu J, Liu M, Wang Y, Zhao Y, Pang Y. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. Int J Antimicrob Agents 2017;49(3):383–6. https://www.ncbi.nlm.nih.gov/pubmed/28188830